Cardiogenic shock (CS) remains the most common cause of mortality in patients with acute
myocardial infarction. The SHOCK trial (Should We Emergently Revascularize Occluded …

Acute myocardial infarction has traditionally been divided into ST elevation or non-ST
elevation myocardial infarction; however, therapies are similar between the two, and the …

Aims The currently available data indicate a drug–drug interaction between morphine and
oral P2Y12 receptor inhibitors, when administered together. The aim of this trial was to …

Interest in the use of mechanical circulatory support for patients presenting with cardiogenic
shock is growing rapidly. The Impella (Abiomed Inc), a microaxial, continuous-flow, short …

Up to 10% of acute coronary syndromes are complicated by cardiogenic shock (CS) with
contemporary mortality rates of 40–50%. The extent of ischemic myocardium has a profound …

Background: The platelet inhibitory effects induced by oral P2Y12 receptor antagonists are
delayed in patients with ST-segment–elevation myocardial infarction undergoing primary …

Background: Standard administration of newer oral P2Y12 inhibitors, including prasugrel or
ticagrelor, provides suboptimal early inhibition of platelet aggregation (IPA) in patients with …

Despite advancements in treatments for acute coronary syndromes over the last 10 years,
they continue to be life-threatening disorders. Currently, the standard of treatment includes …

Background: Platelet inhibitory effects induced by oral P2Y12 receptor antagonists are
delayed in patients with ST-segment elevation myocardial infarction (STEMI) undergoing …

Dual antiplatelet therapy with aspirin and the oral P2Y12 inhibitor clopidogrel as the
cornerstone of treatment for patients with an acute coronary syndrome (ACS) undergoing …